Startups

Isomorphic Labs secures $5B Series C to advance AI-discovered drugs into human trials

DeepMind spinout Isomorphic Labs closed a $5B funding round led by Greenoaks and Sequoia, valuing the AI drug-discovery company at $50B as it moves preclinical candidates toward clinical development.

Last verified:

$5B Series C accelerates Isomorphic’s path from protein folding to clinical medicine

Isomorphic Labs, the AI drug-discovery platform spun from Google DeepMind in 2021, announced a $5 billion Series C funding round led by Greenoaks and Sequoia Capital on November 17, 2026. According to TechCrunch AI, Andreessen Horowitz joined as a new investor, while all existing backers—including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund—participated in the round. Bloomberg previously reported the company was targeting a $50 billion valuation, though Isomorphic did not disclose its official post-money valuation in the announcement.

The funding marks a significant milestone for the biotech venture, arriving six months after its $2.1 billion Series B in May 2026. The capital injection enables Isomorphic to advance AI-discovered drug candidates from preclinical research into human clinical trials—a critical inflection point that separates early-stage drug-discovery platforms from operationalized pharmaceutical development. The company has reported positive preclinical results in oncology and immunology, two of the highest-value therapeutic areas in modern medicine.

Demis Hassabis shifts focus as AlphaFold-backed drug engine gains pharma validation

The Series C coincides with a structural shift at DeepMind’s leadership. Isomorphic founder and CEO Demis Hassabis, who shared the 2024 Nobel Prize in Chemistry with John Jumper for AlphaFold protein-structure prediction work, has formalized his transition from heading DeepMind to leading Isomorphic full-time, while assuming a chairman role at DeepMind. This organizational change underscores Alphabet’s confidence in translating AI-discovered drug candidates into commercial outcomes—a notoriously capital-intensive and risk-laden path that has deterred many AI companies from pursuing end-to-end drug development.

Isomorphic’s core technology builds on the AlphaFold breakthrough, extending protein folding into a broader AI drug-design engine that runs physics-based simulations across chemistry domains. According to TechCrunch AI, the platform has already attracted partnerships with Eli Lilly, Novartis, and Johnson & Johnson—three of the pharmaceutical industry’s largest research-and-development organizations. These collaborations indicate that mature pharma players view Isomorphic’s AI models as credible tools for target discovery and molecule optimization, not merely speculative applications.

Why This Matters

The $5 billion raise signals that biotech investors now believe AI-designed molecules can clear the regulatory and clinical hurdles that have historically bottlenecked drug development. If Isomorphic’s oncology and immunology candidates successfully transition through Phase 1 human trials and beyond, the company would validate a new template for drug discovery: one where AI systems reduce the cost and time-to-first-human-dose by orders of magnitude compared to traditional high-throughput screening. This outcome would likely catalyze follow-on funding rounds in competing AI-biotech startups and attract additional pharma partnerships, fundamentally reshaping how large pharmaceutical companies allocate R&D spending. Conversely, if the clinical transition proves slower or more costly than the preclinical results suggest, the valuation multiples applied to AI drug-discovery platforms would face pressure, potentially constraining capital availability across the sector.

Frequently Asked Questions

What is Isomorphic Labs and how is it connected to DeepMind?

Isomorphic Labs is an AI drug-discovery company spun out of Google DeepMind in 2021. It was founded by Demis Hassabis, who recently transitioned from leading DeepMind to focusing on drug discovery as Isomorphic's CEO while taking a chairman role at DeepMind.

How much has Isomorphic Labs raised in total?

Isomorphic Labs has raised $7.1 billion across funding rounds: a $2.1 billion Series B in May 2026 and the current $5 billion Series C announced on November 17, 2026.

Which pharmaceutical companies is Isomorphic Labs partnering with?

According to TechCrunch AI, Isomorphic has struck deals with pharma giants including Eli Lilly, Novartis, and Johnson & Johnson.

What are the company's current drug candidates targeting?

Isomorphic has reported positive preclinical results in oncology and immunology, with plans to expand into additional therapeutic areas using its AI drug-design engine.

#AI drug discovery #biotech #fundraising #DeepMind spinout #pharma partnerships